📢 NEW PUBLICATION ALERT!
A new article has just been published in The European Journal of Health Economics:
“The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany”
✍️ Author: Giovanni Righetti
This study evaluates the causal impact of Germany’s 2011 AMNOG reform, which introduced a formal Health Technology Assessment (HTA)-based system requiring price negotiations for new drugs based on their added therapeutic value.
🔍 Key findings:
• The AMNOG reform led to a 15.8% reduction in negotiated prices for anticancer drugs in Germany.
• The price decrease is causal and robust, accounting for underlying price trends and cross-country comparisons using a triple-difference approach.
• There is no evidence that manufacturers increased launch prices strategically during the initial free-pricing period to offset later negotiated reductions.
• The effect is specific to Germany, with no comparable price changes observed in control countries.
🎯 Bottom line: This study provides strong causal evidence that HTA-driven price negotiations, like Germany’s AMNOG system, can significantly reduce pharmaceutical prices without triggering strategic price inflation at launch, supporting their role as a key policy tool for sustainable drug pricing.
🔗 Read the full article here:
https://doi.org/10.1007/s10198-026-01924-5